July 23, 2019

Brian Wong
Chief Executive Officer
RAPT Therapeutics, Inc.
561 Eccles Avenue
South San Francisco, CA 94080

       Re: RAPT Therapeutics, Inc.
           Amendment No. 1 to Registration Statement on Form S-1
           Filed July 22, 2019
           File No. 333-232572

Dear Mr. Wong:

      We have reviewed your amended registration statement and have the
comments. In some of our comments, we may ask you to provide us with
information so we
may better understand your disclosure.

       Please respond to this letter by amending your registration statement
and providing the
requested information. If you do not believe our comments apply to your facts
circumstances or do not believe an amendment is appropriate, please tell us why
in your

       After reviewing any amendment to your registration statement and the
information you
provide in response to these comments, we may have additional comments. Unless
we note
otherwise, our references to prior comments are to comments in our July 17,
2019 letter.

Amendment No. 1 to Registration Statement on Form S-1

The Offering, page 9

1.     Please disclose here, if true, that your executive officers, directors
and affiliates will, in
       the aggregate, beneficially own approximately 61.3% of your common stock
       after the closing of this offering without giving effect to any
additional purchases by these
       holders pursuant to their indications of interest to purchase up to
approximately $25.0
       million shares in this offering. In addition, please disclose here the
percentage of your
       shares of common stock that these holders, in the aggregate, will
beneficially own if they
       do purchase $25.0 million shares of common stock in this offering.
 Brian Wong
RAPT Therapeutics, Inc.
July 23, 2019
Page 2
Management's Discussion and Analysis of Financial Condition and Results of
Overview, page 71

2.       We note your response to comments 2 and 3. Please remove statements
that imply an
         expectation of regulatory approval, such as your disclosure on page 71
that compares
         RPT193 to currently marketed injectable biologics and states that
RPT193 is as safe as
         effective as the current standard of care. Such statements are
inappropriate given the stage
         of development of your drug candidates. In addition, please remove
statements, such as
         the statement noted above, that compares your drug candidates to other
drug candidates,
         products or treatments unless you have conducted a head-to-head
clinical study.
       You may contact Sasha Parikh at 202-551-3627 or Jim Rosenberg at
202-551-3679 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Sonia Bednarowski at 202-551-3666 or Dietrich King at 202-551-8071 with
any other

FirstName LastNameBrian Wong                                   Sincerely,
Comapany NameRAPT Therapeutics, Inc.
                                                               Division of
Corporation Finance
July 23, 2019 Page 2                                           Office of
Healthcare & Insurance
FirstName LastName